PMID- 36879380 OWN - NLM STAT- MEDLINE DCOM- 20230417 LR - 20230810 IS - 1097-0045 (Electronic) IS - 0270-4137 (Linking) VI - 83 IP - 7 DP - 2023 May TI - Rezum water vapor therapy for patients with mild, moderate, or severe lower urinary tract symptoms: A retrospective study in a multiethnic population. PG - 713-721 LID - 10.1002/pros.24508 [doi] AB - BACKGROUND: The Rezum System (Rezum) represents a novel, minimally invasive surgical therapy used to treat lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). We evaluated the safety and efficacy of Rezum in patients with mild, moderate, or severe LUTS. METHODS: A single office, retrospective study was conducted on patients from a multiethnic population treated with Rezum between 2017 and 2019. Patients were categorized into three cohorts based on baseline International Prostate Symptom Score (IPSS) LUTS severity: mild LUTS (IPSS /= 20) cohorts. Outcome measures, including IPSS, quality of life (QoL), maximum urinary flow rate (Qmax), postvoid residual (PVR), BPH medication usage, and adverse events (AEs) were collected and analyzed at baseline, 1-, 3-, 6-, and/or 12-months postoperatively. RESULTS: A total of 238 patients were included: 33 with mild LUTS, 109 with moderate LUTS, and 96 with severe LUTS. At 1-month follow-up, the moderate and severe LUTS cohorts saw significant improvements in IPSS (moderate LUTS: -3.0 [-6.0, 1.5], p < 0.001; severe LUTS: -10.0 [-16.0, -5.0], p < 0.001) and QoL (moderate LUTS: -1.0 [-3.0, 0.0], p < 0.001; severe LUTS: -1.0 [-3.0, 0.0], p < 0.001) and improvements remained durable up to 12-months (p < 0.001). The mild LUTS cohort saw significant worsening in IPSS by 2.0 (0.0, 12.0) at 1-month (p = 0.002) but returned to baseline at 3-months (p = 0.114). However, the mild LUTS cohort experienced significant improvements in QoL by -0.5 (-3.0, 0.0) at 3-months (p = 0.035) and nocturia by 0.0 (-1.0, 0.0) at 6-months (p = 0.002), both of which remained durable to 12-months (p < 0.05). Most AEs were transient and nonserious, with gross hematuria (66.5%) being most common. There were no significant differences in QoL point reduction, Qmax improvement, PVR reduction, and AE occurrence between the cohorts at 12-months (p > 0.05). At 12-months, 80.0%, 87.5%, and 66.0% of the patients in the mild, moderate, and severe LUTS cohorts discontinued their BPH medications, respectively. CONCLUSIONS: Rezum provides rapid and durable relief in LUTS in patients with moderate or severe LUTS and can be offered to patients with mild LUTS who have bothersome nocturia and wish to discontinue their BPH medications. CI - (c) 2023 Wiley Periodicals LLC. FAU - Babar, Mustufa AU - Babar M AUID- ORCID: 0000-0001-8490-2260 AD - Albert Einstein College of Medicine, Bronx, New York, USA. AD - DSS Urology, Queens Village, New York, USA. FAU - Loloi, Justin AU - Loloi J AD - Department of Urology, Montefiore Medical Center, Bronx, New York, USA. FAU - Tang, Kevin AU - Tang K AUID- ORCID: 0000-0002-2908-1954 AD - Albert Einstein College of Medicine, Bronx, New York, USA. FAU - Singh, Sandeep AU - Singh S AD - DSS Urology, Queens Village, New York, USA. FAU - Ines, Matthew AU - Ines M AUID- ORCID: 0000-0003-0364-7398 AD - DSS Urology, Queens Village, New York, USA. FAU - Patel, Rutul D AU - Patel RD AD - New York Institute of Technology College of Osteopathic Medicine, Old Westbury, New York, USA. FAU - Iqbal, Nazifa AU - Iqbal N AD - DSS Urology, Queens Village, New York, USA. FAU - Ciatto, Michael AU - Ciatto M AD - DSS Urology, Queens Village, New York, USA. LA - eng PT - Journal Article DEP - 20230306 PL - United States TA - Prostate JT - The Prostate JID - 8101368 RN - 0 (Steam) SB - IM CIN - J Urol. 2023 Sep;210(3):548-550. PMID: 37317776 MH - Male MH - Humans MH - *Prostatic Hyperplasia/complications/surgery/diagnosis MH - Quality of Life MH - Steam MH - Retrospective Studies MH - *Nocturia/complications MH - *Lower Urinary Tract Symptoms/etiology/surgery MH - Treatment Outcome OTO - NOTNLM OT - benign prostatic hyperplasia OT - minimally invasive surgical therapy OT - nocturia OT - quality of life EDAT- 2023/03/07 06:00 MHDA- 2023/04/17 06:41 CRDT- 2023/03/06 23:52 PHST- 2022/07/01 00:00 [revised] PHST- 2022/04/01 00:00 [received] PHST- 2023/02/22 00:00 [accepted] PHST- 2023/04/17 06:41 [medline] PHST- 2023/03/07 06:00 [pubmed] PHST- 2023/03/06 23:52 [entrez] AID - 10.1002/pros.24508 [doi] PST - ppublish SO - Prostate. 2023 May;83(7):713-721. doi: 10.1002/pros.24508. Epub 2023 Mar 6.